These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. RT-PCR for Amplification of Specific Fragments of HIV-1 Genome. de Béthune MP; Hertogs K Methods Mol Med; 2000; 24():269-82. PubMed ID: 21331915 [TBL] [Abstract][Full Text] [Related]
46. Surrogate markers in HIV disease. Peto T J Antimicrob Chemother; 1996 May; 37 Suppl B():161-70. PubMed ID: 8818838 [TBL] [Abstract][Full Text] [Related]
47. Vancouver: optimism, but at a cost. Churchill D; Pym A; Coker R Int J STD AIDS; 1996 Oct; 7(6):385-7. PubMed ID: 8940665 [No Abstract] [Full Text] [Related]
48. Immunological and virological surrogate markers in the evaluation of therapies for HIV infection. Valentine FT; Jacobson MA AIDS; 1990; 4 Suppl 1():S201-6. PubMed ID: 2152568 [No Abstract] [Full Text] [Related]
49. Laboratory markers associated with progression of HIV infection. Gupta V; Gupta S Indian J Med Microbiol; 2004; 22(1):7-15. PubMed ID: 17642679 [TBL] [Abstract][Full Text] [Related]
51. Patients have undetectable HIV after coming off treatment. Hayward P Lancet Infect Dis; 2013 Aug; 13(8):660-1. PubMed ID: 24049782 [No Abstract] [Full Text] [Related]
52. HIV viral load markers in clinical practice. Saag MS; Holodniy M; Kuritzkes DR; O'Brien WA; Coombs R; Poscher ME; Jacobsen DM; Shaw GM; Richman DD; Volberding PA Nat Med; 1996 Jun; 2(6):625-9. PubMed ID: 8640545 [TBL] [Abstract][Full Text] [Related]
54. 4th International Workshop on HIV Drug Resistance. Sardinia, Italy, July 6-9, 1995. Abstracts. J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 3():S1-46. PubMed ID: 8605585 [No Abstract] [Full Text] [Related]
55. Viral load: to treat or not to treat? Steele FR Nat Med; 1995 Oct; 1(10):980. PubMed ID: 7489377 [No Abstract] [Full Text] [Related]
56. Health care: Bring microbial sequencing to hospitals. Peacock S Nature; 2014 May; 509(7502):557-9. PubMed ID: 24877182 [No Abstract] [Full Text] [Related]
57. The New York case: lessons being learned. Volberding PA Ann Intern Med; 2005 May; 142(10):866-8. PubMed ID: 15845950 [No Abstract] [Full Text] [Related]
58. Markers, cofactors and staging systems in the study of HIV disease progression: a review. Portela MC; Simpson KN Mem Inst Oswaldo Cruz; 1997; 92(4):437-57. PubMed ID: 9361736 [TBL] [Abstract][Full Text] [Related]
59. [HIV-1 resistance and the clinical laboratory]. Córdoba J; Esteban RJ; Garijo R; Molina JM; Gobernado M Rev Esp Quimioter; 1999; 12(4):310-316. PubMed ID: 10878522 [No Abstract] [Full Text] [Related]